Tagged: SFO

UK fraud office expects decision on GSK Case Next Year..



I’m going to make a prediction about this..

I think that the UK Serious Fraud Office will either let GSK off the hook completely (due to some technicality of law or loop-hole) or GSK will get off very lightly (a slap on the wrist). Either way, I would be extremely surprised if justice is adequately served.

In a just world, one where corporations like GSK don’t get to operate above the law- the top executives at GSK would all be in jail. However we don’t live in a just world, we love in a corporate driven world, one where corporations get to decide on what laws they can break at a whim, with little consequence from the establishment or the authorities.

It will be interesting to see whether the serious fraud office in the UK has the balls, or even the power, to bring the GSK Goliath to book…

Judging from past examples, of GSK criminality, I won’t hold my breath…

They are the UK’s prized Pharma Cash-cow…

Too many people, in places of power, are generating too much wealth from this cash cow for it- to ever be -put out to pasture…




UK fraud office expects decision on GSK, Rolls-Royce cases next year

LONDON (Reuters) – The UK Serious Fraud Office (SFO) said on Thursday it expects to decide next year whether it will file criminal charges in bribery investigations related to drugs giant GlaxoSmithKline (GSK.L) and aero engine company Rolls-Royce (RR.L).

The SFO launched an investigation into GSK and its subsidiaries in 2014. Britain’s biggest drugmaker has already been fined a record 3 billion yuan ($452 million) by Chinese authorities for paying bribes to doctors to use its drugs.

The SFO’s continued investigation into Rolls-Royce is focusing on individuals after the aero engine maker paid 671 million pounds ($870 million) in January to settle British, U.S. and Brazilian bribery investigations.

David Green, the head of the SFO, told Reuters in an interview that he hoped a decision about charges would be made before he steps down after six years in the job next April.

“I would expect resolution in both these cases in 2018, and hopefully prior to my departure in April,” he said.

Separately, a spokeswoman for the Attorney General’s Office, which is responsible for SFO director appointments, said the recruitment process for Green’s successor had yet to begin. But she said there was “still plenty of time” and that there “will be an appointment in due course”.

Prime Minister Theresa May’s Conservative Party pledged in May to abolish the specialist investigator and prosecutor and roll it into the four-year-old National Crime Agency (NCA) to “strengthen Britain’s response to white collar crime”.

But the proposal drew sharp criticism from white collar crime lawyers, lawmakers and anti-corruption groups and was later dropped from the minority government’s official two-year policy program.

Lawyers said the omission could signal a reprieve for the agency, which in June charged Barclays (BARC.L), one of the country’s biggest banks, and four former senior executives with fraud over undisclosed payments to Qatari investors in 2008.




Could They Get Any More Corrupt?… Apparently Yes!.. GSK Are Consulted About UK Bribery Act…

November 6, 2015 6:53 pm

Government censured over ‘one-sided’ consultation on Bribery Act

The headquarters of the Serious Fraud Office in Westminster.©Charlie Bibby

The government undertook a “widespread, secret and one-sided consultation” that was “hugely damaging to the UK’s reputation”, according to an anti-corruption campaigner who has released emails revealing that key businesses were polled on whether to alter guidance on the Bribery Act.

Most respondents told the Department of Business, Innovation & Skills that they had no major concerns about the Act. One defence contractor went further on the implications of the consultation.

Thales, the French defence electronic company, said: “This survey seems to be sending out a message that if we eased up on bribery, UK plc would win a few more overseas contracts.”

The company added that the answer to that was: “No, in the vast majority of countries; possibly, in some and for certain, in less than a handful of others. But at what cost to the UK’s reputation,” according to emails published on Friday by Corruption Watch after a Freedom of Information request.

Companies including GSK, currently under investigation by the Serious Fraud Office, and Agusta Westland, where two executives were cleared of corruption last year in Italy, took part in the exercise, according to the emails. Both companies said they had no concerns about the legislation or guidance.

The most severe criticism was from the Engineering and Machinery Alliance, which represents small and medium-sized companies and called for more pragmatism.

“To think that bribes do not happen in Asia and Arab countries is naive,” it said. “They are an integral, accepted part of doing business in many of these markets and therefore a necessity if you are going to export to these regions.”

The consultation, which was led by the business department and the National Security Council, sought to determine earlier this year whether the Bribery Act could be made “simpler and/or less costly to follow” and whether its implementation “could better support exporters,” according to the emails.

It follows an attempt two years ago to change guidance on the act, which came into force in 2011 and overhauled Britain’s antiquated anti-corruption legislation.

To think that bribes do not happen in Asia and Arab countries is naive. They are an integral, accepted part of doing business in many of these markets– Engineering and Machinery Alliance

The UK was pressured by the OECD group of advanced economies to introduce the legislation after the scandal of BAE Systems, when Downing Street intervened nearly a decade ago in the Serious Fraud Office investigation of alleged corruption in Saudi Arabia.

The consultation follows other efforts to row back on tough reforms. Last month, the government quietly dropped a plan, strongly supported by the SFO, to extend the act to other types of economic crime.

“The government must not let its deregulation agenda derail its anti-corruption efforts, or cave into a small section of the UK business community,” Corruption Watch said.

“This consultation exercise is hugely damaging to the UK’s reputation and the UK must now show it is prepared to put serious political effort into bolstering the Bribery Act.”

The SFO, the main agency that enforces the act, was not informed of the recent consultation. It declined to comment.

The business department said in a statement: “The government is not reviewing the Bribery Act. We are proud of the Bribery Act and serious about tackling corruption

UK Serious Fraud Office and the GSK 3

By Bob Fiddaman and The Truthman
(Because two heads are better than one)
In 2014 it was announced that the Serious Fraud Office (SFO) were going to be investigating GlaxoSmithKline with regard to their nefarious activities that have recently come to light in countries such as China, UK, USA, Iraq, Poland, Bahrain, Jordan, Kuwait, Syria, Lebanon, Oman, Qatar and the United Arab Emirates.

As with all investigations we rarely get to see what is going on, that’s why I found the following court document surprising, so surprising that I decided to invite long time friend and fellow blogger, the Truthman, on board to help me to some digging. Truthman’s excellent exposé on GSK can be found on his blog, the aptly titled, “GSK, Licence To Kill.”

The court document gives us three names, there may be more employees of GSK, past and present, that may have already been interviewed by the SFO or, as we suspect, many more who may be interviewed in the future.

The three GSK employees, two of them current and one a former employee, are, it appears, not cooperating with the SFO, each claiming that they have a right to be legally represented during those interviews.

According to court documents the three individuals were told by the investigating SFO that they could not have legal representation – the SFO later did a u-turn but told the three that they could not use the services of the same law firm representing GSK with respect to the investigation.

All three asked for a judicial review on the decision claiming that they had a right to use whoever they chose to represent them. The  High Court, after reviewing the original decision, found that the grounds were unarguable.

The three employees.

Whilst it’s important to note that the three individuals are not suspects into GSK’s alleged bribery and corruption, it’s interesting to see the positions they hold at GSK. It’s also interesting that these individuals, if they have nothing to hide, would hold up the process of the SFO investigation on the basis that they wanted their legal representation to come from the same law firm, Arnold & Porter UK LLP. If, the ‘GSK Three’ wished to help the SFO then surely it wouldn’t matter who they were represented by.

So, who are the three?

1. Jason Lord. (No photo available)

Research shows that Lord was, in 2006, GlaxoSmithKline (GSK) Security Adviser in the Corporate Security and Investigations Department.

In 2006, Lord attended and gave a presentation at the Jordan Intellectual Property Association (JIPA), a membership-based association that has organized several IP training events in Jordan. (Web Archive)

For those that don’t know, Jordan is another country currently under investigation. The claims are that GSK staff in Jordan have bribed doctors. The allegations relating to Jordan and also Lebanon were first reported in the Wall Street Journal, which cited emails from a person who first contacted GSK in December. The paper said the emails allege that GSK sales representatives bribed doctors to prescribe drugs and vaccines by issuing free samples to doctors that they were allowed to sell on.

Not much else is known about Jason Lord.

2. Paul Reynolds.

Paul Reynolds, GlaxoSmithKline

According to his LinkedIn page, Reynolds currently holds the position of GSK Head of Respiratory Marketing, UK.

Between July 2010 – March 2012 Reynolds was GSK’s Senior Marketing Director, Seretide (Europe, Asia Pacific, and Emerging Markets)

Seretide  is a product manufactured and marketed by GlaxoSmithKline, it is used to treat Asthma.

In 2014, BBC Panorama aired ‘Who’s Paying Your Doctor?‘ where it was alleged that GSK paid doctors to promote GSK’s asthma drug Seretide in Poland between 2010 and 2012.

Ironically, in 2012, Reynolds became Commercial Director, Retail for GlaxoSmithKline, a position which he held in Warsaw, Poland.

In 2011, Reynolds, wrote an article for the pmlive, a website about the pharmaceutical industry.

Some of his quotes, we feel, were misplaced. Maybe Reynolds was speaking from the heart when he said…

“Companies like GSK began taking action against the mistakes of the past many years ago. I feel that I operate in a company that  works tirelessly to do the right thing, not just to work within the  rules and to restore trust, but to act and operate transparently and  ethically, because it is the right and the only thing that a business  and an industry should do. Pushing at the boundaries against competitors or with customers, whether they are prescribers, payers or patients, is not good business. The industry was still learning to operate within a new space, having previously enjoyed much greater freedom. So, naturally the focus was on understanding how to operate within new rules, without contravening them.”

When I look back at this early part of my marketing career, I see the naivety of some of my actions and of those of people around me, as we tested how far we could go while staying within the remit of the Code. For me now, rules are to be bettered and not tested and this outlook is one I see as the norm today.

We find it interesting that Paul Reynolds mentions the ‘pushing of the boundaries’ early in his career. Was Reynolds suggesting the boundaries of what is ethical perhaps or what is legal? He also says that the industry previously enjoyed ‘greater freedom’, what exactly does he mean here? ‘Greater freedom to do what? Considering  this article was written in 2011 and GSK were yet to be fined for their $3 Billion US fraud felony in 2012, and their China bribe operation in 2014, perhaps Paul Reynolds was being a little premature in his assessment of GSK’s ethical compliance system?

As we mentioned, Reynolds currently holds the position of GSK Head of Respiratory Marketing, UK. Seretide is the UK brand name for Advair, as it is known in the US.

GSK’s Advair is used to prevent asthma attacks, and to treat chronic obstructive pulmonary disease [COPD] and the recent whistleblower suit, that GSK plead guilty to and paid a record $3 billion in fines, shows how they aggressively marketed it with promotional ‘get togethers’ as shown in the video  excerpts [below]

3. Justin Mayger

Justin Mayger, GlaxoSmithKline

Mayger currently holds the position of Director, Compliance and Control Integration at GSK. He was first employed by GSK in 2005 where he took on the position of Senior Business Risk Consultant. Five years later saw Mayger take up the position of Director, Anti-Bribery and Corruption Prevention  (ABAC) at GSK. (LinkedIn)

The role of the ABAC is to investigate allegations as soon as it becomes aware of them. Part of GSK’s policy on bribery and corruption in the business reads…

GSK has zero tolerance towards bribery and corruption. GSK employees shall not make, offer to make, or authorise payment to a third party (e.g. sales agent, distributor or intermediary) with knowledge that all or part of the payment will be offered or given to any individual to secure an improper advantage, obtain or retain business.

All three will now be interviewed by the UK Serious Fraud Office. It’s unknown why the SFO have picked these three individuals to help with their investigation.

Glaxo’s current CEO, Andrew Witty, was the Vice President and General Manager of Marketing of Glaxo Wellcome Inc. [GlaxoWellcome and SmithKline Beecham merged in 2000 to become GlaxoSmithKline.] Some of his responsibilities included, strategy development, marketing execution and new product positioning. Witty and his team were awarded a Medical Marketing Association [MMA] award [Medical Marketer of the Year] in 1998. He also worked in the Company’s International New Products groups, both in the Respiratory and HIV/Infectious disease fields.

Two words – Marketing and Respiratory. Alarm bells anyone?

GSK’s CEO, Andrew Witty, said in a statement about the record $3 billion payout that “Today brings to resolution difficult, long-standing matters for (Glaxo). Whilst these originate in a different era for the company, they cannot and will not be ignored. On behalf of (Glaxo), I want to express our regret and reiterate that we have learnt from the mistakes that were made,” 

We think the SFO need to look further afield if they wish to get to the bottom of the whole Seretide promotional activities of GSK, if indeed that is their intention here.

Collectively, myself and co-writer, Truthman, strongly urge the SFO to interview Andrew Witty if they wish to know more about the respiratory drug promotion from GlaxoSmithKline. Let’s face it, the guy must have a wealth of experience in all matters relating to the respiratory side of the business at the global pharmaceutical giant. Failing that, maybe the SFO should contact Peter Humphrey, he was hired by GSK China to investigate bribery claims, despite GSK denying that the claims were true – they later went on to plead guilty to the claims.

We would be extremely surprised if Andrew Witty ends up anywhere near a prosecution, given that lawyers representing GSK seem to be doing their very best to stall the investigation.

GSK have huge power and sway in the UK, they are a major cash cow, and one only has to look at  the board to see that there are many Knights of the realm (Sir’s) who  make most of the executive decisions at GSK. In fact, GSK have so many Knights stewarding the company we could be forgiven if we mistook it as some kind of pseudo-Camelot, except these Knights certainly aren’t as chivalrous.

Another Revolving Door

Trying to get a successful prosecution against GSK, or any individuals operating within GSK, may prove to be difficult given that Kathleen Harris, a former SFO lawyer, was recently hired as a partner at US-headquartered firm Arnold & Porter, the very same law firm who are defending Glaxo and who wished to represent the Glaxo three during their interviews. (Source) During her time at the SFO she supervised and provided strategic oversight to a number of high-level investigations and prosecutions. She also played a key role in developing seminal guidelines on critical issues, including plea negotiations, civil remedies, civil recovery and corporate prosecutions.

Upon leaving the SFO to join Arnold & Porter, Harris said, “Arnold & Porter has a prominent group of white collar defense lawyers with extensive criminal law experience on the prosecutorial side from the U.S. Justice Department and other regulatory agencies, as well as on the defense side. It’s great to be a part of this team.” (Source)

It wouldn’t surprise us if the current SFO investigation comes down to some sort of plea negotiation between both parties. Both the Truthman and I hope we are wrong. History, however, may repeat itself as this is not the first time we have seen a revolving door between prosecution and defence where GSK have been involved in litigation or investigation. (see US Attorney General Eric Holder and the Revolving Door)

Contrast the SFO investigation with the MHRA’s investigation into GSK and you will see such a huge difference. The SFO wish to seek the truth by actually investigating claims, where the MHRA carried out a near five-year investigation into GlaxoSmithKline, commencing in 2003 and ending in 2008, and, well, really didn’t do much to find the whole truth.

GSK had failed to report in a timely manner adverse event data from clinical trials in children of its antidepressant, Seroxat (Paxil). (See Restoring Study 329) After nearly five long years the MHRA decided not to prosecute, not only that, it emerged that the MHRA did not even bother to interview any employees from GSK.

At the time, I, Bob Fiddaman, asked the MHRA, under the terms of the Freedom of Information Act, the following question…

“Why were MHRA enforcement investigators unable to question GSK staff?”

The MHRA replied…

Under UK criminal law suspects in criminal investigations can not be compelled to answer questions, they have a right to remain silent. Lengthy negotiations were conducted with solicitors acting for individual members of GSK staff and for GSK itself with a view to persuading them to attend interviews under caution. The conclusion of the correspondence was that all the potential interviewees indicated that they would not attend an interview under caution.

The individual suspects (as opposed to the corporate entity GSK) could have been arrested and required to attend an interview under caution. However they could still not be compelled to answer questions and, given that their solicitors had clearly indicated that they would not answer questions, the investigation team concluded that there was nothing to gain by carrying out arrests.

The near five-year investigation resulted in the MHRA sending GSK a “You’ve been naughty, but it’s okay” type of letter, a letter that, the then current GSK CEO, JP Garnier, responded to by stating, that ‘Glaxo had done nothing wrong.’

Talk about arrogance!

Maybe the MHRA should take a lesson from the Serious Fraud Office or, maybe the MHRA need to get better counsel?

Those in-the-know know why the MHRA did not prosecute GSK and it had nothing to do with their official explanation.

Let’s hope that Messrs Lord, Reynolds and Mayger can provide the SFO with information they need to find the ringleader involved in the fraud and bribery, let’s hope they (SFO) can show the British drug regulator how investigations should be carried out. Let’s hope the SFO’s investigation leads to criminal prosecutions and, hopefully, some custodial sentences.

With a former SFO employee now working for Arnold & Porter, our hopes may be dashed.

I hope I can make it across the border. I hope to see my friend and shake his hand. I hope the pacific is as blue as it has been in my dreams. I hope.Red, Shawshank Redemption

Bob Fiddaman & The Truthman.

GSK Whistle Blowers? : Contact The Serious Fraud Office Confidentially And Blow That Whistle!

From Bob Fiddaman’s Blog: 



Wednesday, May 28, 2014

A Message From the UK Serious Fraud Office re GSK

GlaxoSmithKline plc investigation

27 May 2014

The Director of the SFO has opened a criminal investigation into the commercial practices of GlaxoSmithKline plc and its subsidiaries.

Whistleblowers are valuable sources of information to the SFO in its cases.  We welcome approaches from anyone with inside information on all our cases including this one – we can be contacted through our secure and confidential reporting channel, which can be accessed via the SFO website.

Notes to editors:

The SFO’s secure reporting channel can be accessed here: https://report.sfo.gov.uk/sfo-confidential—provide-information-in-confidence.aspx or via our website home page, www.sfo.gov.uk

The Serious Fraud Office is an independent government department responsible for investigating and prosecuting serious and complex fraud, bribery and corruption. It is headed by the Director, David Green CB QC, who exercises powers under the superintendence of the Attorney General. These powers are derived from the Criminal Justice Act 1987.

The SFO Press Office can be contacted on press.office@sfo.gsi.gov.uk or 020 7239 7316 / 7004 (out of hours: +44 (0) 7557 009 842)


I actually went out and purchased a bottle of wine last night on the strength of this latest news.

The SFO may want to investigate the British drug regulator, The MHRA, too. It was they who, after a four-year investigation of GlaxoSmithKline, decided to let Glaxo off with a warning letter. No criminal charges were brought against GSK…even after the MHRA learned during their investigation that GSK had knowingly withheld safety data regarding children taking the antidepressant Seroxat [Known as Paxil in the US]

The MHRA’s four year investigation into GlaxoSmithKline failed on a catastrophic level.

Alistair Benbow, who was then Head of European Psychiatry at GSK, claimed on National TV that Seroxat could be safe in children even though his company did not have a licence to recommend it to children. [1]

All the SFO need to do is request disclosure from GSK. Emails, documents and, more importantly, the notes taken by GSK’s pharmaceutical reps during their visits to doctors and psychiatrists. Did Glaxo’s UK reps offer the same incentives to British doctors as GSK’s American, Chinese, Polish and Iraqi reps did?

Once they have these in their possession then I’m sure they will be able to retrace who said what and who they said it to.

It is imperative that the SFO obtain these documents.

The MHRA should have requested the same documents but why would they? They rely on pharmaceutical money, in fact, they are fully funded by the pharmaceutical industry.

The SFO are calling on whistleblowers – good luck. The carrot being dangled isn’t really as attractive as the carrot dangled in front of whistleblowers in the US.

I suspect the SFO are merely following up on the alleged bribery in China – they need to do more than follow-up though.

GlaxoSmithKline is infested, it’s driven by a culture where sales mean everything.

I do hope the SFO turn over every item they come across, I do hope this is not just them following up on GSK’s foreign violations.

There are plenty of experts out there who could help the SFO’s investigation, whether they choose to use them is another matter.

No stone unturned is the order of the day here. The SFO will, no doubt, face tough opposition from the current UK government. Deals may be struck given that Glaxo’s chairman, Andrew Witty, and the current Prime Minister, David Cameron, are friends and business acquaintances. [2]

One thing is certain though. The eyes of the world are watching.


Bob Fiddaman

[1] Seroxat – The Liars? [Video]

[2] Cronyism, Chinese Style

GSK says faces UK serious fraud investigation


GSK says faces UK serious fraud investigation

May 27 (Reuters) – GlaxoSmithKline Plc said on Tuesday that Britain’s Serious Fraud Office (SFO) has opened a formal criminal investigation into its commercial practices.

GSK said in a statement that it would cooperate fully with the SFO and was committed to operating its business to the highest ethical standards.

The statement gave no further details about the investigation. (Reporting by Andy Bruce, editing by David Milliken